Dustin Phan
Analyst
Analyst
Los Angeles, USA
+6 year(s) experience
Dustin joined Datamonitor Healthcare in the summer of 2015. One of the highlights of his role has been analyzing the development of novel therapies from the early pre-clinical and clinical phases, through final approval and marketing authorization. Having been involved in cancer research as a graduate student, Dustin is fascinated by new compounds or mechanisms of action and their impact on the oncology treatment space, both from a clinical and commercial viewpoint.
He has a Bachelor of Science in Applied and Computational Mathematics and a PhD in Biological Sciences, both from the University of California, Irvine.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
Topic business-strategies drug-approval drug-development-landscape